NCT00035152已完成3 期
A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.
Bristol-Myers Squibb111 个研究点 分布在 1 个国家目标入组 444 人开始时间: 2000年6月最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 444
- 试验地点
- 111
研究概览
简要总结
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma.
This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly.
The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Past or current history of neoplasm other than the entry diagnosis. Exceptions are curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or other cancers treated by surgery or radiation with a disease free survival longer than 5 years.
- •Patients who have undergone surgery less than 3 weeks prior to enrollment.
- •History of serious cardiac disease not adequately controlled.
- •Patients with serious active infections or other serious underlying medical condition.
- •Uncontrolled diabetes mellitis.
研究者
研究点 (111)
Loading locations...
相似试验
已完成
2 期
Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLCNon Small Cell Lung CancerNCT00259675University of Saskatchewan100
已完成
3 期
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerFallopian Tube CancerPrimary Peritoneal CancerOvarian CancerNCT03635489Hoffmann-La Roche100
已完成
3 期
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.Non-Small-Cell Lung CarcinomaNCT00148395Aktion Bronchialkarzinom e.V.280
已完成
3 期
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerHER2-Positive Breast CarcinomaHormone Receptor-Positive Breast CarcinomaStage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7NCT02003209National Cancer Institute (NCI)315
已完成
2 期
Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck NeoplasmNCT00623558Seoul National University Hospital92